RT Journal Article
T1 Advances and highlights in biomarkers of allergic diseases.
A1 Ogulur, Ismail
A1 Pat, Yagiz
A1 Ardicli, Ozge
A1 Barletta, Elena
A1 Cevhertas, Lacin
A1 Fernandez-Santamaria, Ruben
A1 Huang, Mengting
A1 Bel Imam, Manal
A1 Koch, Jana
A1 Ma, Siyuan
A1 Maurer, Debbie J
A1 Mitamura, Yasutaka
A1 Peng, Yaqi
A1 Radzikowska, Urszula
A1 Rinaldi, Arturo O
A1 Rodriguez-Coira, Juan
A1 Satitsuksanoa, Pattraporn
A1 Schneider, Stephan R
A1 Wallimann, Alexandra
A1 Zhakparov, Damir
A1 Ziadlou, Reihane
A1 Brüggen, Marie-Charlotte
A1 van de Veen, Willem
A1 Sokolowska, Milena
A1 Baerenfaller, Katja
A1 Zhang, Luo
A1 Akdis, Mubeccel
A1 Akdis, Cezmi A
K1 COVID-19
K1 allergen immunotherapy
K1 allergic diseases
K1 biomarkers
K1 precision medicine
AB During the past years, there has been a global outbreak of allergic diseases, presenting a considerable medical and socioeconomical burden. A large fraction of allergic diseases is characterized by a type 2 immune response involving Th2 cells, type 2 innate lymphoid cells, eosinophils, mast cells, and M2 macrophages. Biomarkers are valuable parameters for precision medicine as they provide information on the disease endotypes, clusters, precision diagnoses, identification of therapeutic targets, and monitoring of treatment efficacies. The availability of powerful omics technologies, together with integrated data analysis and network-based approaches can help the identification of clinically useful biomarkers. These biomarkers need to be accurately quantified using robust and reproducible methods, such as reliable and point-of-care systems. Ideally, samples should be collected using quick, cost-efficient and noninvasive methods. In recent years, a plethora of research has been directed toward finding novel biomarkers of allergic diseases. Promising biomarkers of type 2 allergic diseases include sputum eosinophils, serum periostin and exhaled nitric oxide. Several other biomarkers, such as pro-inflammatory mediators, miRNAs, eicosanoid molecules, epithelial barrier integrity, and microbiota changes are useful for diagnosis and monitoring of allergic diseases and can be quantified in serum, body fluids and exhaled air. Herein, we review recent studies on biomarkers for the diagnosis and treatment of asthma, chronic urticaria, atopic dermatitis, allergic rhinitis, chronic rhinosinusitis, food allergies, anaphylaxis, drug hypersensitivity and allergen immunotherapy. In addition, we discuss COVID-19 and allergic diseases within the perspective of biomarkers and recommendations on the management of allergic and asthmatic patients during the COVID-19 pandemic.
YR 2021
FD 2021-09-27
LK http://hdl.handle.net/10668/18517
UL http://hdl.handle.net/10668/18517
LA en
DS RISalud
RD Apr 5, 2025